ArticleEuropean heart journal2023
Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score.
Article in European heart journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Recurrent VTE in patients with thrombophilia after stopping anticoagulation: a systematic review and meta-analysis.Blood advances · 2026Pooled it
- Robustness of placebo-controlled trials of extended-duration direct oral anticoagulant therapy for secondary venous thromboembolism prevention.Internal and emergency medicine · 2026Pooled it
- Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis.European heart journal · 2026Pooled it
- Risk of Recurrent Venous Thromboembolism in Patients with Cancer: An Individual Patient Data Meta-analysis and Development of a Prediction Model.Thrombosis and haemostasis · 2025Pooled it
- Article
- Bleeding Events During Anticoagulation After Acute Pulmonary Embolism: Real-Life Experience.Medicina (Kaunas, Lithuania) · 2026Article
- Expanding outpatient eligibility using a narrow definition of cancer in the Pulmonary Embolism Severity Index.Research and practice in thrombosis and haemostasis · 2026Article
- Accuracy of machine learning models in predicting recurrent venous thromboembolism: a systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2026Review
- Machine learning in bleeding risk assessment for low-molecular-weight heparin or fondaparinux: a predictive model study.Scientific reports · 2026Observational
- How to determine the optimal duration of anticoagulation for VTE: an evidence-based decision-analytical approach.Blood advances · 2026Article
- Contemporary Challenges in Venous Thromboembolism: Evolving Populations and Implications for Management and Risk Stratification.Journal of clinical medicine · 2026Review
- Pyruvate kinase M2 promotes venous thrombosis by enhancing SNAP23-mediated platelet exocytosis and consequent NETosis.Blood advances · 2026Article
- Managing patients with a history of arterial disease and new venous thromboembolism.Hematology. American Society of Hematology. Education Program · 2025Article
- Coagulopathy and platelet abnormalities in patients with inflammatory bowel disease.The Korean journal of internal medicine · 2025Review
- The current status and future perspective of extended anticoagulation therapy for cancer-associated venous thromboembolism.Journal of thrombosis and thrombolysis · 2025Review
- Assessing Health-Related Quality of Life of Patients with Pulmonary Embolism with the Heart QoL Questionnaire.Medicina (Kaunas, Lithuania) · 2025Article
- Article
- Identification of key genes related to lymphangiogenesis in venous thromboembolism through transcriptomics and verification by RT-qPCR.Frontiers in medicine · 2025Article
- Direct Oral anticoagulants in pulmonary thromboembolism therapy: the generalization-individualization dilemma and the path to risk stratification-a perspective.Frontiers in medicine · 2025Article
- The Recurrence of Venous Thromboembolism in Obstructive Sleep Apnea: A Narrative Review.Canadian respiratory journal · 2025Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
15 authors at 9 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsDeciding to stop or continue anticoagulation for venous thromboembolism (VTE) after initial treatment is challenging, as individual risks of recurrence and bleeding are heterogeneous. The present study aimed to develop and externally validate models for predicting 5-year risks of recurrence and bleeding in patients with VTE without cancer who completed at least 3 months of initial treatment, which can be used to estimate individual absolute benefits and harms of extended anticoagulation. METHODS AND
resultsCompeting risk-adjusted models were derived to predict recurrent VTE and clinically relevant bleeding (non-major and major) using 14 readily available patient characteristics. The models were derived from combined individual patient data from the Bleeding Risk Study, Hokusai-VTE, PREFER-VTE, RE-MEDY, and RE-SONATE (n = 15,141, 220 recurrences, 189 bleeding events). External validity was assessed in the Danish VTE cohort, EINSTEIN-CHOICE, GARFIELD-VTE, MEGA, and Tromsø studies (n = 59 257, 2283 recurrences, 3335 bleeding events). Absolute treatment effects were estimated by combining the models with hazard ratios from trials and meta-analyses. External validation in different settings showed agreement between predicted and observed risks up to 5 years, with C-statistics ranging from 0.48-0.71 (recurrence) and 0.61-0.68 (bleeding). In the Danish VTE cohort, 5-year risks ranged from 4% to 19% for recurrent VTE and 1% -19% for bleeding.
conclusionThe VTE-PREDICT risk score can be applied to estimate the effect of extended anticoagulant treatment for individual patients with VTE and to support shared decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.